GLP-1 Medications and Rheumatoid Arthritis: What the 2025 Research Actually Shows

You’ve done everything right. You take your methotrexate. You’re on a biologic. And still — the morning stiffness lingers, the flares keep coming, and the fatigue never fully lifts. If that sounds like your life with rheumatoid arthritis, I want to talk to you about something I’m watching change outcomes in my practice every single week.

You already know the names — Ozempic, Wegovy, Mounjaro, Zepbound. Everyone’s talking about them for weight loss and diabetes. What almost no one is talking about is what the 2025 research now shows these same medications can do for rheumatoid arthritis — and why, for a carefully chosen group of patients, they may be one of the most useful additions to RA treatment we’ve had in years.

I’m Dr. Diana Girnita, a double board-certified rheumatologist with a PhD in immunology and over 20 years of experience. Let me walk you through what’s real, what’s still early, and how to think about it honestly.

Can extra weight actually make rheumatoid arthritis worse?

Yes — and this is the piece most patients are never told.

Rheumatoid arthritis and body weight are not two separate problems. They feed each other. A large study by Ohno and colleagues, published in Nature in 2020, found that the risk of developing RA rises with every roughly 5 kg of weight gain or every inch added to your waistline.

Here’s why. Your fat tissue is not just storage. Fat cells are biologically active little factories, and they pump out a steady stream of inflammatory molecules — IL-6, TNF-alpha, and IL-1. Those are the exact same molecules that drive rheumatoid arthritis. They’re the same molecules your expensive biologic is designed to block.

So picture the tug-of-war: your biologic is working to quiet inflammation, while your fat tissue keeps refilling the tank around the clock. This is one reason obesity is linked to higher RA disease activity, harder-to-reach remission, and lower response to treatment. In fact, more than 30% of North American patients with RA also carry obesity, and this group tends to cycle through more medications before finding relief.

There’s also a practical problem: most biologics for RA come in fixed doses that aren’t adjusted for body weight. A one-size-fits-all dose can leave heavier patients underdosed without anyone realizing it.

That’s the missing piece. Sometimes the answer isn’t a stronger biologic — it’s addressing the metabolic inflammation feeding the fire.

How do GLP-1 medications work in rheumatoid arthritis?

GLP-1 receptor agonists were built to mimic a gut hormone that lowers blood sugar and appetite. But the newer research shows they do something rheumatology cares about a lot: they lower inflammation — and part of that effect appears to be independent of weight loss.

In RA specifically, a few mechanisms matter most:

• They turn down the inflammatory supply from fat tissue. Losing even 5–10% of body weight meaningfully reduces IL-6, TNF-alpha, and IL-1 output — so your DMARD or biologic has less to fight.
• They act directly on inflammation pathways. A 2024 scoping review by Karacabeyli and Lacaille found GLP-1 medications inhibit the NF-kB pathway — one of the body’s master inflammation switches — in RA and psoriasis cell models, even before weight changes.
• They reduce insulin resistance. A 2017 study by Tejera-Segura and colleagues showed RA patients often have hidden insulin resistance driven by chronic inflammation. Breaking that cycle helps calm the whole system.

If you want the full deep-dive on all five anti-inflammatory mechanisms across every type of arthritis, I cover that in my main GLP-1 and arthritis guide. Here, I want to keep the focus on RA.

What does the 2025 research show for rheumatoid arthritis?

This is where the conversation shifts from “interesting theory” to “real clinical data.”

The UCLA study every RA patient should know about. In September 2025, researchers at UCLA published a study in ACR Open Rheumatology (Kellner and colleagues). They followed 173 RA patients with overweight or obesity who were prescribed and actually took a GLP-1 medication (semaglutide or tirzepatide) between 2018 and 2024, and compared them to 42 patients who were prescribed one but never took it. After up to a year:

• The patients who took the medication had significantly greater improvements in RA disease activity and pain than the control group.
• They lost significantly more weight and had better cholesterol and blood sugar (HbA1c).
• Within the treated group, inflammation markers ESR and CRP dropped, along with LDL and triglycerides.

The honest caveat: this was a retrospective, single-center study — helpful and encouraging, but not a randomized controlled trial. And importantly, nearly one-third of the treated patients stopped the medication, most often because of gastrointestinal side effects like nausea. That’s a real-world number worth knowing before you start.

Larger database signals. At ACR Convergence 2025, additional research reinforced the picture. One large study found that semaglutide use was associated with improved joint outcomes, raising the possibility of a disease-modifying effect. Another found that RA patients on DMARDs who also took a GLP-1 (or SGLT2) medication had fewer disease flares — pointing again toward a genuine anti-inflammatory benefit, not just weight loss.

The inflammation-marker data. A 2025 systematic review and meta-analysis of tirzepatide (Masson and colleagues, Reviews in Endocrine and Metabolic Disorders) found that across seven randomized trials, tirzepatide reduced hsCRP by about 33% and IL-6 by about 18% compared to placebo — and the effect held even at the lowest 5 mg dose. One nuance worth being straight about: at later time points, some of that CRP and IL-6 drop tracked with weight loss, while some of the early benefit appeared before major weight change. The science is still sorting out exactly how much is weight-driven versus direct.

Do GLP-1 medications lower heart risk in rheumatoid arthritis?

This may be the most underappreciated benefit for RA patients.

If you have RA, your risk of heart attack and stroke is already higher than average — the chronic inflammation of RA damages blood vessels over time, and it’s the leading cause of death in this population. Add obesity and insulin resistance, and that risk compounds.

GLP-1 medications are already proven to reduce cardiovascular events in people with obesity and diabetes. In the UCLA RA study, the treated patients saw their cardiovascular risk profile improve — better cholesterol, blood sugar, and weight. For a disease that quietly threatens the heart, that’s not a side benefit. That’s central.

Can a GLP-1 medication let me lower my RA medication dose?

This is the question I get most, so let me be very clear.

GLP-1 medications do not replace your DMARD or your biologic. They are not a substitute for methotrexate, and they are not a substitute for a TNF inhibitor or any other biologic. Anyone who tells you otherwise is misinformed.

What they can do — and what the UCLA data and my own patients suggest — is make your existing treatment work better by removing the metabolic inflammation undercutting it. For some carefully selected patients, that opens the door to eventually reducing the drug burden rather than escalating it: a lower biologic frequency, a smaller methotrexate dose, or getting off chronic steroids. That’s a conversation to have with your rheumatologist, tracked with objective disease activity scores — never a do-it-yourself taper.

What about microdosing GLP-1 for rheumatoid arthritis?

Here’s the part I find most exciting, and the most underused in rheumatology right now.

You don’t necessarily need dramatic weight loss to benefit. Because some of the anti-inflammatory action works independently of weight, even very small doses — what clinicians call microdosing — can calm the inflammatory signaling. Instead of pushing to the full weight-loss dose, some patients start at a low dose, just enough to nudge the metabolic and inflammatory pathways, without major appetite suppression.

This is especially relevant for RA patients who aren’t significantly overweight but still have metabolic inflammation — insulin resistance, prediabetes, or a stubbornly elevated CRP despite adequate drug doses.

A composite example from my practice: I’ve cared for a patient — maximized on both a DMARD and a biologic, still flaring several times a month, exhausted, in pain. A few months after starting a low-dose GLP-1, her flares dropped to about one a month, her energy came back, and we began tapering her medications instead of adding more. This is a composite, and individual results vary widely — but it captures a pattern I now see often enough that I ask about metabolic inflammation at nearly every RA visit.

If microdosing is where your questions are, I go deeper in my article on GLP-1 microdosing for inflammatory arthritis.

Semaglutide vs. tirzepatide for RA: what’s the difference?

Patients mix these up constantly, so here’s the short version.

Both were used in the UCLA RA study. The “right” one depends on your other conditions, insurance coverage, tolerance, and goals — which is exactly why this belongs in a rheumatologist’s hands, not a weight-loss clinic’s.

Who should be cautious?

GLP-1 therapy isn’t for everyone with RA. A few honest cautions:

• GI side effects are common — nausea, and in the UCLA study nearly a third of patients stopped for this reason. Slow dose titration helps.
• Rapid weight loss can briefly trigger a gout flare if you also have gout, because fast fat breakdown temporarily raises uric acid. This usually settles as weight stabilizes, but it needs a physician who understands both conditions.
• It’s an add-on, not a rescue. If your RA is active, you still need appropriate DMARD or biologic therapy first.

This is why personalized, monitored care matters. Starting a GLP-1 for RA is a clinical decision that should account for your disease activity, your other conditions, and your goals.

The bottom line

Ozempic and Wegovy are semaglutide. Mounjaro and Zepbound are tirzepatide. For rheumatoid arthritis, they are not replacements for your DMARD or biologic — but the 2025 research from centers like UCLA suggests they can be a powerful complement: less disease activity, fewer flares, lower inflammation markers, better cholesterol and blood sugar, and reduced cardiovascular risk — sometimes even at low doses.

If your RA medications are doing something but not enough, and your flares and fatigue keep coming back, there may be a metabolic piece of your puzzle no one has addressed yet. That’s exactly the conversation worth having with a rheumatologist who understands both inflammation and metabolic health.

References

1. Ohno T, et al. Association between body mass index and the risk of rheumatoid arthritis. Nature (Scientific Reports). 2020. Link
2. Kellner DA, Dente E, Tran V, et al. Effect of Glucagon-Like Peptide 1 Receptor Agonists on Patients With Rheumatoid Arthritis. ACR Open Rheumatol. 2025 Sep;7(9):e70103. Link
3. Karacabeyli D, Lacaille D. Glucagon-Like Peptide 1 Receptor Agonists in Patients With Inflammatory Arthritis or Psoriasis: A Scoping Review. J Clin Rheumatol. 2024;30(1):26-31. Link
4. Masson W, Lobo M, Nogueira JP, et al. Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis. Rev Endocr Metab Disord. 2025. Link
5. American College of Rheumatology. New Research at ACR Convergence 2025 Highlights Potential of GLP-1 Therapies in Rheumatic Disease Management. 2025. Link
6. Tejera-Segura B, et al. Relationship between insulin resistance and rheumatoid arthritis. Arthritis Res Ther. 2017. Link

This article is for educational purposes and does not constitute medical advice. Diana Girnita, MD, PhD, FACR — double board-certified rheumatologist, founder of Rheumatologist OnCall (telehealth practice serving women across multiple US states, in person in California), PhD in immunology.